2 unknown. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Unknown 2 |
| Phase 1 | 1 | Unknown 1 |
Follow GLIDE: new trials by email Literature Review of GLIDE trials Research Report on GLIDE
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| GLIDE Regimen Followed by ASCT for Aggressive NK/T Cell Lymphoma GLIDE - Lymphoma, Extranodal NK-T-Cell | Phase 2 | Unknown | Sichuan University | 60 | 2017-06-01 | 2017-11-08 |
| Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion) GLIDE - Hematologic Cancer, Relapse Leukemia | Phase 1 / Phase 2 | Unknown | Ciusss de L'Est de l'Île de Montréal | 20 | 2017-02-06 | 2017-12-06 |
Hematologic Neoplasms (1) · Hodgkin Disease (1) · Leukemia, Myeloid, Acute (1) · Lymphoma, Extranodal NK-T-Cell (1) · Lymphoma, Non-Hodgkin (1) · Multiple Myeloma (1) · Myelodysplastic Syndromes (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Ciusss de L'Est de l'Île de Montréal (1) · Sichuan University (1)
Canada (1) · China (1)
Denis-Claude Roy, MD PhD (1) · Silvy Lachance, MD (1) · Ting Liu, MD (1)